• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence

    6/1/26 9:25:36 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email

    NETANYA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the expansion of its Zorronet subsidiary's autonomous C5ISR suite to support fully secure on-premise, hybrid, and closed-loop deployments for defense, security, and critical infrastructure. The expanded offering enables organizations to run the full Zorronet C5ISR suite inside hardened sites, secured intranets, and restricted infrastructure without relying on the public cloud.

    The expansion reflects growing demand for autonomous command-and-control systems that can function locally inside secured infrastructure, a priority highlighted by US President Donald Trump's push to accelerate secure AI adoption in defense and critical infrastructure protection.

    These organizations can't expose their security data to public-cloud systems or the wider internet because of regulatory and cybersecurity requirements. As a result, they have faced limitations adopting cloud-dependent AI and C5ISR systems at hardened sites where speed and local control are essential.

    Zorronet's expanded suite is positioned within the growing C5ISR market, where demand is being driven by defense modernization, real-time situational awareness, secure data integration, and faster command decision-making. Industry estimates show that the market is expected to grow to $189 billion by 2030 as defense, security, and critical infrastructure operators invest in more connected and autonomous command capabilities.

    The architecture enables autonomous command-and-control functions, local AI processing, edge computing, and response coordination to run on local GPU-based servers inside hardened sites, restricted intranets, and command centers. The system supports real-time inference at the edge, keeping alert validation and response coordination within controlled networks. While cloud infrastructure remains an important option, the expanded offering adds local and hybrid deployment paths for sites whose security, bandwidth, legal, or continuity requirements call for these functions to run inside protected infrastructure.

    Zorronet is designed to work with existing security devices, integrating cameras, sensors, drones, IoT devices, access-control systems, robotic assets, and other security infrastructure into a unified C5ISR suite. The system converts complex security and surveillance data into clear real-time alerts, commands, tasking, and responses that field teams can quickly understand and act on. These functions would traditionally require multiple people in a command center, thereby helping teams move faster from detection to execution. Zorronet can also trigger response workflows and issue commands autonomously inside the secured network.

    "AI is becoming essential to modern security and defense operations, but many organizations cannot simply connect their security data to the public cloud," said Idan Wasserman, CEO of Zorronet. "Militaries, security organizations, and critical infrastructure operators often need command-and-control automation to run inside closed-loop intranets or restricted networks, where data stays under their control. This expansion brings Zorronet's autonomous C5ISR capabilities into those sites, turning complex security and surveillance data into clear intelligence and commands, helping teams move from detection to action faster, while automating work that would otherwise sit with a large control-room team.

    "BiomX's focus is building technologies that can function in the kinds of high-security settings where reliability, response speed, and local control matter," said Michael Oster, CEO of BiomX. "Zorronet's expanded on-premise capabilities reflect how security and critical infrastructure organizations are approaching AI and command-and-control systems. As more sites move toward autonomous monitoring and response, there is growing demand for systems built around local control, continuity, and faster execution."

    About BiomX

    BiomX Inc. (NYSE:PHGE) is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

    About Zorronet

    Zorronet, a BiomX company, develops AI-powered command-and-control software that helps security and operations teams turn cameras, sensors, drones, and IoT devices into a unified real-time operating picture. The system uses artificial intelligence and machine learning to detect, classify, and prioritize events, incidents, and potential threats, helping teams understand what is happening and coordinate faster responses. Designed for both defense and civilian security applications, Zorronet's systems are currently used in military sites, critical infrastructure, municipalities, smart cities, industrial facilities, large public venues, and more. By converting large volumes of sensor and system data into clear alerts and recommended actions, Zorronet enables operators to manage and respond to complex activity and threats while reducing false alarms across everything from individual facilities to national borders.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended".  Forward-looking statements include statements regarding Zorronet's AI-powered command-and-control capabilities; the potential benefits, performance, scalability, security, and deployment of its on-premise, hybrid, closed-loop, edge-AI, and low-bandwidth architecture; the ability of Zorronet's technologies to support defense, security, critical infrastructure, transportation, smart city, industrial, and remote-site applications.

    These statements are based on current expectations, estimates, assumptions, and beliefs of BiomX and Zorronet management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, among others, Zorronet's ability to develop, test, deploy, commercialize, and scale its technologies; the ability to convert technical validations, supplier approvals, or collaboration opportunities into commercial deployments or revenue; BiomX's going concern qualification in its recent financial statements; customer adoption; changes in cybersecurity, regulatory, procurement, and operational requirements; competition; technical, integration, performance, security, or deployment challenges; BiomX's ability to execute its strategic transition; and other risks described in BiomX's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K as supplemented by the 10-K/A filed with the SEC on April 30, 2026, current report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2026 Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings. BiomX undertakes no obligation to update or revise any forward-looking statements, except as required by law.

    Contact

    Yair Ohayon

    Yairo@biomx.com 



    Primary Logo

    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Yeganeh Reuven sold $3,350,000 worth of shares (670,000 units at $5.00) and converted options into 670,000 shares (SEC Form 4)

    4 - BiomX Inc. (0001739174) (Issuer)

    3/13/26 4:30:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bidas Liat Cohavi

    3 - BiomX Inc. (0001739174) (Issuer)

    3/3/26 9:27:51 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    6/5/26 4:30:42 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by BiomX Inc.

    SCHEDULE 13D/A - BiomX Inc. (0001739174) (Subject)

    5/28/26 6:13:53 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    5/28/26 8:09:55 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence

    NETANYA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the expansion of its Zorronet subsidiary's autonomous C5ISR suite to support fully secure on-premise, hybrid, and closed-loop deployments for defense, security, and critical infrastructure. The expanded offering enables organizations to run the full Zorronet C5ISR suite inside hardened sites, secured intranets, and restricted infrastructure without relying on the public cloud. The expansion reflects growing demand for autonomous command-and-control systems that can function locally inside secured infrastructure, a priority highlighted by US President Donald Trump's push to

    6/1/26 9:25:36 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

    NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

    4/10/26 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care